Takuma Furukawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Takuma Furukawa has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Megumi Hara
Department of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
10 shared publications Kenji Wakai
6 shared publicationsKiyonori Kuriki
6 shared publicationsTakashi Tamura
6 shared publications- Akiko Matsumoto
Saga University
5 shared publications Hiroaki Ikezaki
5 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Elsevier in SSRN Electronic Journal
Beyond Population-Average Alcohol Risk: ALDH2/ADH1B Genotype-Specific Associations with Mortality in Japan
Background: Population-level dose–response curves may not capture heterogeneity in alcohol-related risk across alcohol-metabolism genotypes. We examined whether aldehyde dehydrogenase 2 (ALDH2) rs671 (G>A) and alcohol dehydrogenase 1B (ADH1B) rs1229984 (A>G) modify associations between alcohol intake and mortality. Methods: Within the Japan Multi-Institutional Collaborative Cohort Study, we conducted a case-cohort analysis in a base cohort of 75,841 cancer-free Japanese adults, including 4,528 deaths and a subcohort of 9,813. ALDH2 rs671 and ADH1B rs1229984 were genotyped. Hazard ratios (HRs) for all-cause, cancer, and cardiovascular disease (CVD) mortality were estimated with Børgan type II weighted Cox models, with alcohol intake modelled by categories and restricted cubic splines. Findings: During a median 12·9-year follow-up, deaths included 2,408 from cancer and 703 from CVD. Overall, alcohol intake was positively associated with all-cause and cancer mortality, whereas the CVD association was apparently U-shaped. Cancer mortality increased more steeply among ALDH2 rs671 GA carriers than among GG carriers, with a stronger per-10-g/day association (interaction HR 1·08, 95% confidence interval 1·03–1·12). In combined-genotype analyses, cancer mortality rose at lower intake levels and most prominently among rs671 GA/AA and rs1229984 AG/GG carriers. Genotype-specific CVD patterns were less consistent. Interpretation: Alcohol-related risk assessment may need to account for alcohol-metabolism genotype, particularly ALDH2 rs671. Risk communication based solely on reported intake may underestimate susceptibility among individuals carrying certain alcohol-metabolism genotypes.
- 31 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBeyond Population-Average Alcohol Risk: ALDH2/ADH1B Genotype-Specific Associations with Mortality in Japan
Background: Population-level dose–response curves may not capture heterogeneity in alcohol-related risk across alcohol-metabolism genotypes. We examined whether aldehyde dehydrogenase 2 (ALDH2) rs671 (G>A) and alcohol dehydrogenase 1B (ADH1B) rs1229984 (A>G) modify associations between alcohol intake and mortality. Methods: Within the Japan Multi-Institutional Collaborative Cohort Study, we conducted a case-cohort analysis in a base cohort of 75,841 cancer-free Japanese adults, including 4,528 deaths and a subcohort of 9,813. ALDH2 rs671 and ADH1B rs1229984 were genotyped. Hazard ratios (HRs) for all-cause, cancer, and cardiovascular disease (CVD) mortality were estimated with Børgan type II weighted Cox models, with alcohol intake modelled by categories and restricted cubic splines. Findings: During a median 12·9-year follow-up, deaths included 2,408 from cancer and 703 from CVD. Overall, alcohol intake was positively associated with all-cause and cancer mortality, whereas the CVD association was apparently U-shaped. Cancer mortality increased more steeply among ALDH2 rs671 GA carriers than among GG carriers, with a stronger per-10-g/day association (interaction HR 1·08, 95% confidence interval 1·03–1·12). In combined-genotype analyses, cancer mortality rose at lower intake levels and most prominently among rs671 GA/AA and rs1229984 AG/GG carriers. Genotype-specific CVD patterns were less consistent. Interpretation: Alcohol-related risk assessment may need to account for alcohol-metabolism genotype, particularly ALDH2 rs671. Risk communication based solely on reported intake may underestimate susceptibility among individuals carrying certain alcohol-metabolism genotypes.
- Open Access
- 2 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353127
Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial
Submacular hemorrhage (SMH), which may arise from age-related macular degeneration, retinal arterial macroaneurysm, and other causes, can result in severe vision loss and central visual field impairment. Although tissue plasminogen activator (tPA) is used off-label to treat SMH in many countries, no formulation has been approved for this indication. Because early intervention is critical when tPA is used for SMH, limited access to centers that can provide this treatment may delay care and reduce treatment opportunities. Decentralized clinical trials (DCTs) reduce or eliminate the need for participants to travel to trial sites. We therefore designed the investigator-initiated SACLA trial to evaluate subretinal tPA for SMH. The DCT framework is intended to reduce logistical barriers related to the disease severity and rarity. The SACLA trial is a phase II multicenter, open-label, single-arm surgical study with a pre-post comparison design (jRCT2071250003). Twenty eligible participants will undergo pars plana vitrectomy followed by subretinal injection of 0.1 mL (8,000 IU) of tPA. Participants will remain hospitalized at the trial site until the primary outcome, change in central foveal thickness (CFT) from baseline at Week 1, is assessed. Thereafter, follow-up visits will be conducted at either the trial site or partner sites within the DCT framework. Secondary efficacy outcomes include change in CFT from baseline, presence of a foveal hemorrhage measuring at least 1 disc diameter, best-corrected visual acuity (BCVA), and change in BCVA from baseline at Weeks 4 and 12. Adverse events will be collected throughout the 12-week observation period to assess safety. The protocol and related study documents were reviewed and approved by the Saga University Hospital Institutional Review Board. This study is designed to generate prospective evidence on the feasibility, short-term anatomical response, and safety of subretinal tPA for SMH.
- 2 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353127
Open AccessProtocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial
Submacular hemorrhage (SMH), which may arise from age-related macular degeneration, retinal arterial macroaneurysm, and other causes, can result in severe vision loss and central visual field impairment. Although tissue plasminogen activator (tPA) is used off-label to treat SMH in many countries, no formulation has been approved for this indication. Because early intervention is critical when tPA is used for SMH, limited access to centers that can provide this treatment may delay care and reduce treatment opportunities. Decentralized clinical trials (DCTs) reduce or eliminate the need for participants to travel to trial sites. We therefore designed the investigator-initiated SACLA trial to evaluate subretinal tPA for SMH. The DCT framework is intended to reduce logistical barriers related to the disease severity and rarity. The SACLA trial is a phase II multicenter, open-label, single-arm surgical study with a pre-post comparison design (jRCT2071250003). Twenty eligible participants will undergo pars plana vitrectomy followed by subretinal injection of 0.1 mL (8,000 IU) of tPA. Participants will remain hospitalized at the trial site until the primary outcome, change in central foveal thickness (CFT) from baseline at Week 1, is assessed. Thereafter, follow-up visits will be conducted at either the trial site or partner sites within the DCT framework. Secondary efficacy outcomes include change in CFT from baseline, presence of a foveal hemorrhage measuring at least 1 disc diameter, best-corrected visual acuity (BCVA), and change in BCVA from baseline at Weeks 4 and 12. Adverse events will be collected throughout the 12-week observation period to assess safety. The protocol and related study documents were reviewed and approved by the Saga University Hospital Institutional Review Board. This study is designed to generate prospective evidence on the feasibility, short-term anatomical response, and safety of subretinal tPA for SMH.
- Open Access
- 12 January 2026
- Published by Elsevier in Public Health
- Vol. 252, 106142
Educational disparities in mortality mediated by modifiable behavioral factors: Findings from the Japan Multi-Institutional Collaborative Cohort Study
- 12 January 2026
- Published by Elsevier in Public Health
- Vol. 252, 106142
Open AccessEducational disparities in mortality mediated by modifiable behavioral factors: Findings from the Japan Multi-Institutional Collaborative Cohort Study
- Open Access
- 1 January 2026
- Published by Japan Epidemiological Association in Journal of Epidemiology
- p. JE20260061
Serum Urate and Kidney Function in Japanese Cohorts: Mendelian Randomization and Biomarker-Dependent Associations of a URAT1 Loss-of-Function Variant
Background: Experimental studies have linked elevated serum urate (SUA) to kidney injury; however, Mendelian randomization (MR) studies and randomized trials have not consistently supported a causal effect on kidney outcomes. Japanese populations are enriched for the URAT1 loss-of-function variant rs121907892, allowing evaluation of a biologically specific question related to tubular urate transport. We examined the association of genetically predicted SUA with kidney function and, separately, the association of rs121907892 with kidney function measures in Japanese cohorts.Methods: We performed a two-sample MR analysis using 34 genome-wide significant SUA-associated variants from BioBank Japan. Genetic associations with SUA were obtained from the Japan Multi-Institutional Collaborative Cohort Study (n=10,428), and associations with kidney function were obtained from the Tohoku Medical Megabank Organization cohort (n=47,066). Kidney function was assessed using creatinine- and cystatin C-based estimated glomerular filtration rate (eGFR). We also evaluated the association of rs121907892 with these measures.Results: Polygenic MR showed no evidence of an association between genetically predicted SUA and kidney function, with null findings for creatinine-based eGFR (inverse-variance weighted β=−0.031; 95% confidence interval [CI], −0.138 to 0.075; P=0.56) and cystatin C-based eGFR (β=−0.020; 95% CI, −0.123 to 0.084; P=0.71). In contrast, the rs121907892 A allele was associated with higher creatinine-based eGFR (β=0.047; 95% CI, 0.005 to 0.089; P=0.03), but not with cystatin C-based eGFR (β=−0.002; 95% CI, −0.044 to 0.040; P=0.97).Conclusions: Polygenic MR provided no evidence that genetically predicted SUA has a major causal effect on kidney function in Japanese cohorts. The rs121907892 findings indicate a biomarker-dependent, variant-specific association.
- 1 January 2026
- Published by Japan Epidemiological Association in Journal of Epidemiology
- p. JE20260061
Open AccessSerum Urate and Kidney Function in Japanese Cohorts: Mendelian Randomization and Biomarker-Dependent Associations of a URAT1 Loss-of-Function Variant
Background: Experimental studies have linked elevated serum urate (SUA) to kidney injury; however, Mendelian randomization (MR) studies and randomized trials have not consistently supported a causal effect on kidney outcomes. Japanese populations are enriched for the URAT1 loss-of-function variant rs121907892, allowing evaluation of a biologically specific question related to tubular urate transport. We examined the association of genetically predicted SUA with kidney function and, separately, the association of rs121907892 with kidney function measures in Japanese cohorts.Methods: We performed a two-sample MR analysis using 34 genome-wide significant SUA-associated variants from BioBank Japan. Genetic associations with SUA were obtained from the Japan Multi-Institutional Collaborative Cohort Study (n=10,428), and associations with kidney function were obtained from the Tohoku Medical Megabank Organization cohort (n=47,066). Kidney function was assessed using creatinine- and cystatin C-based estimated glomerular filtration rate (eGFR). We also evaluated the association of rs121907892 with these measures.Results: Polygenic MR showed no evidence of an association between genetically predicted SUA and kidney function, with null findings for creatinine-based eGFR (inverse-variance weighted β=−0.031; 95% confidence interval [CI], −0.138 to 0.075; P=0.56) and cystatin C-based eGFR (β=−0.020; 95% CI, −0.123 to 0.084; P=0.71). In contrast, the rs121907892 A allele was associated with higher creatinine-based eGFR (β=0.047; 95% CI, 0.005 to 0.089; P=0.03), but not with cystatin C-based eGFR (β=−0.002; 95% CI, −0.044 to 0.040; P=0.97).Conclusions: Polygenic MR provided no evidence that genetically predicted SUA has a major causal effect on kidney function in Japanese cohorts. The rs121907892 findings indicate a biomarker-dependent, variant-specific association.
- 20 November 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 357-367
Liver diseases and low serum albumin as potential confounders in the association between low total cholesterol and elevated all-cause and cancer mortality: The Japan Multi-Institutional Collaborative Cohort (J-MICC) study
- 20 November 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 357-367
Liver diseases and low serum albumin as potential confounders in the association between low total cholesterol and elevated all-cause and cancer mortality: The Japan Multi-Institutional Collaborative Cohort (J-MICC) study
- Open Access
- 3 May 2025
- Published by Springer Nature in npj Metabolic Health and Disease
- Vol. 3 (1) , 1-8
Comparison of polygenic risk scores for type 2 diabetes developed from different ancestry groups
Polygenic risk scores (PRS) are useful for assessing disease risk; however, knowledge about their effectiveness among Asian and other populations is limited. This study aimed to compare the classification accuracy of PRSs for type 2 diabetes (T2D-PRS) developed from different ancestry groups using genotype data from 14,083 Japanese participants. Participants’ scores were calculated using T2D-PRS models, and logistic regression analysis and receiver operating characteristic curves were assessed. The odds ratio of diabetes per 1 standard deviation increase in PRS was 2.18 and 1.55 for the Japanese and European T2D-PRSs, respectively. The area under the curve (AUC) for the Japanese T2D-PRS was 0.781, whereas that for the European T2D-PRS was 0.738 (P < 0.001). Additionally, age-stratified analysis showed higher AUCs in younger than older age groups. The PRS developed from matched ancestry populations has high classification accuracy for diabetes and is particularly useful for the early detection of high-risk individuals with diabetes.
- 3 May 2025
- Published by Springer Nature in npj Metabolic Health and Disease
- Vol. 3 (1) , 1-8
Open AccessComparison of polygenic risk scores for type 2 diabetes developed from different ancestry groups
Polygenic risk scores (PRS) are useful for assessing disease risk; however, knowledge about their effectiveness among Asian and other populations is limited. This study aimed to compare the classification accuracy of PRSs for type 2 diabetes (T2D-PRS) developed from different ancestry groups using genotype data from 14,083 Japanese participants. Participants’ scores were calculated using T2D-PRS models, and logistic regression analysis and receiver operating characteristic curves were assessed. The odds ratio of diabetes per 1 standard deviation increase in PRS was 2.18 and 1.55 for the Japanese and European T2D-PRSs, respectively. The area under the curve (AUC) for the Japanese T2D-PRS was 0.781, whereas that for the European T2D-PRS was 0.738 (P < 0.001). Additionally, age-stratified analysis showed higher AUCs in younger than older age groups. The PRS developed from matched ancestry populations has high classification accuracy for diabetes and is particularly useful for the early detection of high-risk individuals with diabetes.
- Open Access
- 6 November 2024
- Published by MDPI AG in Preprints.org
Impact of Pre-Vaccination Active Vitamin D Levels on COVID-19 mRNA Vaccine-Induced Immunity in a Japanese Cohort
Background/Objectives: Low blood vitamin D levels have been linked to COVID-19 severity; however, data on the effects of vitamin D on vaccine immunogenicity remain limited. This study evaluated the impact of baseline serum 1α, 25-(OH)2 vitamin D, a bioactive form with controlled blood concentrations, on vaccine response. Methods: From June to September 2021, we measured active vitamin D levels in 88 Japanese workers and students before vaccination with BNT162b2 or mRNA-1273. We assessed SARS-CoV-2 spike protein S1 IgG and IgM levels and antigen-specific INF-γ-releasing cells from pre-vaccination up to 8 months post-second dose. Results: Active vitamin D levels ranged from 33.7 to 99.8 pg/mL, 60.2% above the Japanese reference range (20–60 pg/mL). In a mixed model accounting for repeated measures and sub-cohort random effects and following fixed effects, vaccine type, weeks post-vaccination, age, sex, ALDH2 gene polymorphism, height, smoking, ethanol intake, exercise, stress, steroid use, allergies, dyslipidemia, active vitamin D was negatively associated with anti-S1 IgG and IgM (p < 0.001) but positively with INF-γ-releasing cell counts (p = 0.003). Conclusions: As the robustness of cellular immunity is independent of viral mutations, 1,25-(OH)2 vitamin D levels above the reference range may enhance vaccine-induced COVID-19 protection in the long term.
- 6 November 2024
- Published by MDPI AG in Preprints.org
Open AccessImpact of Pre-Vaccination Active Vitamin D Levels on COVID-19 mRNA Vaccine-Induced Immunity in a Japanese Cohort
Background/Objectives: Low blood vitamin D levels have been linked to COVID-19 severity; however, data on the effects of vitamin D on vaccine immunogenicity remain limited. This study evaluated the impact of baseline serum 1α, 25-(OH)2 vitamin D, a bioactive form with controlled blood concentrations, on vaccine response. Methods: From June to September 2021, we measured active vitamin D levels in 88 Japanese workers and students before vaccination with BNT162b2 or mRNA-1273. We assessed SARS-CoV-2 spike protein S1 IgG and IgM levels and antigen-specific INF-γ-releasing cells from pre-vaccination up to 8 months post-second dose. Results: Active vitamin D levels ranged from 33.7 to 99.8 pg/mL, 60.2% above the Japanese reference range (20–60 pg/mL). In a mixed model accounting for repeated measures and sub-cohort random effects and following fixed effects, vaccine type, weeks post-vaccination, age, sex, ALDH2 gene polymorphism, height, smoking, ethanol intake, exercise, stress, steroid use, allergies, dyslipidemia, active vitamin D was negatively associated with anti-S1 IgG and IgM (p < 0.001) but positively with INF-γ-releasing cell counts (p = 0.003). Conclusions: As the robustness of cellular immunity is independent of viral mutations, 1,25-(OH)2 vitamin D levels above the reference range may enhance vaccine-induced COVID-19 protection in the long term.
- Open Access
Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID-19 Vaccine: Prospective Observation in the Japanese General Population
We previously reported a reduced humoral immune response to the COVID-19 vaccines. Subsequently, we observed a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant through a web-based retrospective survey. Based on these findings, we hypothesized that rs671 variant was beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we assessed cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline after one to three doses, whereas subcohort 2 (19 participants) had two observations before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model (183 observations from 45 participants), including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. Our sequential observational studies suggest a beneficial effect of the rs671 variant in SARS-CoV-2 infection via enhanced cellular immune response, providing a potential basis for optimizing preventive measures and drug development.
Open AccessAsian Flush Gene Variant Enhances Cellular Immunogenicity of COVID-19 Vaccine: Prospective Observation in the Japanese General Population
We previously reported a reduced humoral immune response to the COVID-19 vaccines. Subsequently, we observed a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant through a web-based retrospective survey. Based on these findings, we hypothesized that rs671 variant was beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we assessed cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline after one to three doses, whereas subcohort 2 (19 participants) had two observations before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model (183 observations from 45 participants), including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. Our sequential observational studies suggest a beneficial effect of the rs671 variant in SARS-CoV-2 infection via enhanced cellular immune response, providing a potential basis for optimizing preventive measures and drug development.
- Open Access
- 20 August 2024
- Published by MDPI AG in Preprints.org
Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population
Because we observed a reduced humoral immune response to the COVID-19 vaccine and subsequently discovered a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant, we hypothesized that rs671 is beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we evaluated cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline and after one to three doses, whereas subcohort 2 (19 participants) had two observations, before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant, but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model, including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. There is lower humoral and higher cellular immunity against SARS-CoV-2 in rs671 variant carriers compared to non-carriers, providing a potential basis for optimizing preventive measures and drug discovery.
- 20 August 2024
- Published by MDPI AG in Preprints.org
Open AccessAsian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General Population
Because we observed a reduced humoral immune response to the COVID-19 vaccine and subsequently discovered a lower susceptibility to COVID-19 in individuals carrying the ALDH2 rs671 variant, we hypothesized that rs671 is beneficial for cellular immunity against COVID-19. Using the IFN-γ enzyme-linked immunospot (ELISPOT) assay, we evaluated cellular immunity before and after COVID-19 vaccination in two subcohorts of a previously reported cohort. Subcohort 1 (26 participants) had six repeated observations at baseline and after one to three doses, whereas subcohort 2 (19 participants) had two observations, before and after the third dose. ELISPOT counts at six months after the second dose increased from baseline in carriers of the rs671 variant, but not in non-carriers. A positive effect of rs671 on ELISPOT counts was estimated using a mixed model, including the random effect of subcohort, repeated measures, and fixed effects of vaccine type, age, sex, height, lifestyle, steroid use, and allergic disease. There was no association between ELISPOT counts and specific IgG levels, suggesting a limitation in estimating protective potential by humoral response. There is lower humoral and higher cellular immunity against SARS-CoV-2 in rs671 variant carriers compared to non-carriers, providing a potential basis for optimizing preventive measures and drug discovery.
- Open Access
- 19 September 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 79 (2)
Association Between the Appendicular Extracellular-to-Intracellular Water Ratio and All-Cause Mortality: A 10-Year Longitudinal Study
The appendicular extracellular-to-intracellular water ratio (A-E/I) is a potential marker of skeletal muscle quality, reflecting the balance of water distribution between the extracellular and intracellular compartments of the appendicular limb regions. A-E/I has been increasingly used in recent studies; however, its association with adverse outcomes remains unclear. This study investigated the potential association between A-E/I and all-cause mortality. A prospective cohort study of 8 015 middle-aged and older adults (comprised of 4 755 women, aged 45–74 years) residing in a Japanese community was conducted. The baseline assessment was performed between 2010 and 2012, and the follow-up period lasted until July 2022. A-E/I and skeletal muscle mass were measured using segmental bioelectrical impedance spectroscopy. Handgrip strength (HGS) was measured using a Smedley-type dynamometer. Lifestyle, medical history, and physical activity were assessed by questionnaire and accelerometer. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for each quartile (Q) of A-E/I were estimated using the multivariable Cox regression model. During a 10.5-year median follow-up, the mortality rates were 8.9 and 3.6 per 1 000 person-years for men (292 deaths) and women (174 deaths), respectively. A-E/I quartiles were positively associated with all-cause mortality in both sexes (men: Q1, HR: 1.0 [95% CI: reference], Q4, HR: 1.8 [1.1–2.9], ptrend < .05; women, Q4, HR: 2.2 [1.3–3.8], ptrend < .01). This association remained significant after further adjustment for skeletal muscle mass and HGS (ptrend < .05). Our findings suggest that A-E/I serves as an early predictive marker for mortality in middle-aged and older Japanese adults.
- 19 September 2023
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 79 (2)
Open AccessAssociation Between the Appendicular Extracellular-to-Intracellular Water Ratio and All-Cause Mortality: A 10-Year Longitudinal Study
The appendicular extracellular-to-intracellular water ratio (A-E/I) is a potential marker of skeletal muscle quality, reflecting the balance of water distribution between the extracellular and intracellular compartments of the appendicular limb regions. A-E/I has been increasingly used in recent studies; however, its association with adverse outcomes remains unclear. This study investigated the potential association between A-E/I and all-cause mortality. A prospective cohort study of 8 015 middle-aged and older adults (comprised of 4 755 women, aged 45–74 years) residing in a Japanese community was conducted. The baseline assessment was performed between 2010 and 2012, and the follow-up period lasted until July 2022. A-E/I and skeletal muscle mass were measured using segmental bioelectrical impedance spectroscopy. Handgrip strength (HGS) was measured using a Smedley-type dynamometer. Lifestyle, medical history, and physical activity were assessed by questionnaire and accelerometer. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for each quartile (Q) of A-E/I were estimated using the multivariable Cox regression model. During a 10.5-year median follow-up, the mortality rates were 8.9 and 3.6 per 1 000 person-years for men (292 deaths) and women (174 deaths), respectively. A-E/I quartiles were positively associated with all-cause mortality in both sexes (men: Q1, HR: 1.0 [95% CI: reference], Q4, HR: 1.8 [1.1–2.9], ptrend < .05; women, Q4, HR: 2.2 [1.3–3.8], ptrend < .01). This association remained significant after further adjustment for skeletal muscle mass and HGS (ptrend < .05). Our findings suggest that A-E/I serves as an early predictive marker for mortality in middle-aged and older Japanese adults.